Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Helaba in connection with financing of an acquisition in real estate
Mandate

Vinge has advised Helaba in connection with financing of an acquisition in real estate

June 16, 2017 Banking and Finance

TRIUVA Kapitalverwaltungsgesellschaft mbH, Germany’s leading real estate fund manager, has acquired from Slussgården the city property Lammet 17, located right next to Drottninggatan and Kungsgatan.

The property has 6,700 square meters of office and retail space and Fastighetsvärlden estimates that the price amounts to a bit over 450 million SEK. Catella and Foyen have been advisors to Slussgården and JLL, Roschier, King & Spalding, WSP and Rödl & Partner have been advisors to Triuva. Vinge has advised Landesbank Hessen-Thüringen Girozentrale (Helaba) in connection with the financing of the acquisition.

Vinge’s team consisted of Mikael Ståhl, Helena Håkansson, André Isacson and Ludvig Wettergren.

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

 Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

 Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026